Five years after COVID-19 outbreak, China has a new health concern: the sudden outbreak of HMPV in the country. According to sources, the viral infection is growing at an exponential rate, thereby overloading health facilities and crematories, all of which could be seen online through social media posts and videos that have surfaced on the viral network. Amid these concerns, other respiratory illnesses like influenza A, Mycoplasma pneumoniae, and COVID-19 are said to be also circulating simultaneously with the same conditions, making a heavy strain on the health services. As of this, neither the Chinese government nor the WHO has given official warnings or declared any emergency in these cases.

To combat this upsurge, Chinese health authorities have implemented a pilot system to track cases of pneumonia with unknown origins. This new initiative was launched by China's disease control agency to increase preparedness for respiratory outbreaks during the winter months, a drastic change from the way the nation responded to the COVID-19 pandemic.

This outbreak has affected mostly vulnerable populations, including children whose immune systems are still developing and elderly persons who have a pre-existing respiratory disease. The symptoms of HMPV tend to be those of a cold or flu-like illness, characterized by fever, coughing, and nasal congestion. In some cases, these infections can develop into bronchitis or pneumonia, which significantly increase the risk of complications for individuals with diseases like asthma or COPD.

Despite the similarities to COVID, this virus is very different and was infact identified way back in 2001 and it has been circulating in the entire world since many years. HMPV is not a new virus, and far less worrisome.

Read for HMPV Virus Symptoms , Causes , Treatment and Prevention

What is Human Metapneumovirus (HMPV)?

First identified in the Netherlands in 2001, human metapneumovirus is a respiratory RNA virus within the Paramyxoviridae family. It is a seasonal virus, most actively circulating during the winter and spring seasons. This virus is responsible for one of the most significant causes of hospitalization in the acute respiratory infection (ARI) category among young children, after RSV.

Research indicates that almost all children older than five years have been infected with HMPV, although the immunity developed against subsequent infections is partial. Though it is more of a cold-season disease, cases have been reported throughout the year, with the prevalence of the disease fluctuating every year.

Is HMPV Contagious?

HMPV is commonly spread through contaminated respiratory droplets from infected person to person often by cough, sneeze, or the transfer of aerosolized microorganisms from touch of contaminated fingers on doorknobs and toys. Similar to RSV and influenza within the United States, HMPV follows an annual peak or surge that mostly occurs during winters and springs in many parts.

Human metapneumovirus Symptoms

HMPV infections are highly similar to some of the classic symptoms of 'common cold', they include:

• Fever
• Coughing
• Nasal congestion
• Runny nose
• Sore throat
• Nausea and vomiting

Most symptoms of bronchiolitis go away in a few days. However, more severe cases may lead to complications such as bronchitis or pneumonia, or even life-threatening conditions. Sometimes, young children may suffer from severe bronchiolitis that can be fatal.

Who Is Most at Risk?

While HMPV can affect all age groups, it significantly affects the following:

Those with immature immune systems are highly susceptible to developing severe complications like bronchiolitis or pneumonia.

Individuals with conditions such as COPD, asthma, or pulmonary fibrosis have a higher chance of developing serious symptoms.

People who are undergoing chemotherapy or have recently received an organ transplant are highly vulnerable.

Also Read: What Is Disease X? Preparing For The Next Global Threat

How Is HMPV Diagnosed and Treated?

Diagnosis of HMPV is usually based on a physical examination, patient history, and laboratory tests. In severe cases, advanced diagnostic techniques, like bronchoscopy, are applied to confirm the virus. Treatment is usually symptomatic as there are no specific antiviral therapies or vaccines for HMPV. Some treatments according to the American Lung Association include:

- Over-the-counter medications for relieving fever and pain.

- Inhalers or corticosteroids to control wheezing or harsh coughing.

- Prednisone is the prescription medication only in extreme conditions.

Human Metapneumovirus (HMPV) vs. COVID-19 HMPV and COVID-19 have similarities in their transmission modes and respiratory symptoms. HMPV is a seasonal virus, mostly surfacing during winter and spring. COVID-19, on the other hand, is a year-round virus, with emerging variants.

Surprisingly, the number of cases for other respiratory viruses, such as HMPV, rose drastically during this time as restrictions against COVID-19 relaxed. Scientific evidence shows that during the lockdowns, fewer instances of contact with regular viruses resulted in a vulnerability to them, including HMPV, after restrictions eased.

Is HMPV Preventable?

The only prevention from the virus, however is to avoid contracting it in the first place, particularly for high-risk populations. Dr. Sunil Kumar K, Lead Consultant - Interventional Pulmonology explains, "Preventive strategies include maintaining good hand hygiene, wearing masks in crowded places, and practicing respiratory etiquette, such as covering coughs and sneezes. It's also advisable to avoid close contact with individuals exhibiting respiratory symptoms. Given the absence of a vaccine, these measures are crucial in controlling the spread of the virus."

"While HMPV shares transmission characteristics with COVID-19, such as spread through respiratory droplets, it is generally less severe. However, co-circulation with other respiratory pathogens, including influenza and Mycoplasma pneumonia, as reported in China, can complicate clinical outcomes and pose additional challenges to public health systems.

Continuous surveillance and public awareness are vital in managing this outbreak. Learning from the COVID-19 pandemic, early detection, transparent communication, and adherence to preventive measures are key to mitigating the impact of HMPV and safeguarding public health."

Individuals with chronic conditions of the respiratory system should keep their environment, very clean and shy away from contaminated areas.

As respiratory illnesses continue to rise in China, health experts stress the importance of proactive measures and public awareness. While HMPV is typically mild, its potential to cause severe complications in vulnerable groups underscores the need for vigilance. For now, a combination of symptom management, robust healthcare systems, and effective monitoring initiatives will be critical in managing this growing health challenge.

Dr. Sunil Kumar K is the Lead Consultant - Interventional Pulmonology at Aster CMI Hospital, Bangalore in India

Human Metapneumovirus and Other Respiratory Viral Infections during Pregnancy and Birth, Nepal. Emerg Infect Dis. 2017

Human metapneumovirus and respiratory syncytial virus: subtle differences but comparable severity. Infect Dis Rep. 2010

Human Metapneumovirus (hMPV). American Lung Association.

More than three million children around the world are thought to have died in 2022 as a result of infections that are resistant to antibiotics, new research has found. While these infections impact kids across the world, those in Africa and Southeast Asia are most at risk. Antimicrobial resistance (AMR) develops when the microbes that cause infections evolve so that antibiotic drugs no longer work. As per the World Health Organisation (WHO), it is "one of the top global public health and development threats."

A new study now reveals the toll that AMR is taking on children. Using data from multiple sources, including the World Health Organization (WHO) and the World Bank, researchers calculated that there were more than three million child deaths in 2022 linked to drug-resistant infections. Experts say this new study highlights a more than tenfold increase in AMR-related infections in children in just three years. Experts opine that these numbers could have been made worse by the impact of the COVID pandemic.

Antimicrobial resistance (AMR) threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi.

AMR occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines, making infections harder to treat and increasing the risk of disease spread, severe illness and death. As a result, the medicines become ineffective and infections persist in the body, increasing the risk of spread to others.

Antimicrobials - including antibiotics, antivirals, antifungals and antiparasitics - are medicines used to prevent and treat infections in humans, animals and plants. Microorganisms that develop antimicrobial resistance are sometimes referred to as “superbugs”.

As antibiotic resistance increases, even common infections could become difficult to treat. For example, some doctors have already reported patients needing hospitalization for simple urinary tract infections. This rise in resistance could lead to more complications in hospitals, longer stays, and higher medical costs.

For their study, the researchers examined over 858,000 bacterial isolates collected between 2004 and 2021 from 83 countries, with more than 100,000 samples from children. The study was published in the journal SSRN. The study highlights significant geographic and temporal variations in pediatric AMR, underscoring the need for targeting several countries as compared to others.

What Is AMR?

Antibiotic resistance is a global health crisis, reducing the effectiveness of treatments for common infections. The 2022 GLASS report revealed alarming resistance rates: 42% for cephalosporin-resistant *E. coli* and 35% for methicillin-resistant *Staphylococcus aureus*. In 2020, 1 in 5 urinary tract infections caused by *E. coli* were resistant to standard antibiotics. Resistance in *Klebsiella pneumoniae* and rising use of last-resort drugs like carbapenems are further worsening the situation, with projections indicating a twofold increase in resistance by 2035.

Drug resistance isn’t limited to bacteria. WHO is closely monitoring resistant fungal infections, notably *Candida auris*, which is difficult to treat and linked to high mortality. HIV drug resistance, often due to poor treatment adherence or drug interactions, compromises antiretroviral therapy. Similarly, multidrug-resistant tuberculosis (MDR-TB) remains a severe public health threat, with limited access to effective treatments. Only 40% of those needing treatment for drug-resistant TB received it in 2022.

Malaria control is challenged by resistance to artemisinin-based therapies in Asia and Africa. Meanwhile, drug resistance in neglected tropical diseases (NTDs) like leprosy and leishmaniasis threatens global eradication efforts. Strengthened surveillance, stewardship, and development of second-line treatments are essential to curb this growing menace.

In a country where the vitality of the president tends to serve as a proxy-in for credibility as a leader, President Donald J. Trump — now in his second term and the oldest president to hold office in U.S. history — is again making cognitive health the focal point of the nation's dialogue. Speaking on board Air Force One headed to West Palm Beach, the 78-year-old commander-in-chief made a public proclamation that he had "got every answer right" on a cognitive test administered during his annual check-up at Walter Reed Medical Center. "Good heart. Good soul. I felt I was in very good shape," said Trump, continuing that he went out of his way to take the test as a way of distinguishing himself from political rivals.

But what is this mental test actually — and what does it really tell us about a sitting president's mental acuity, particularly in the tough and high-wire job of Commander-in-Chief?

The president addressed openly to journalists on board during the trip to his home in West Palm Beach, Florida, assertively declaring, "I got every answer right." This comment has once again sparked public curiosity regarding the nature and importance of cognitive testing, particularly among aging political figures.

"I’m in very good shape — good heart, good soul, very good soul," President Trump told the White House press pool, emphasizing his physical and mental wellness. Not only did he point out the good results of his physical, but he also used the opportunity to differentiate himself from his political peers by mentioning that he took a cognitive test voluntarily — something he says his predecessors, former President Joe Biden and Vice President Kamala Harris, had declined to do.

This is not the first time President Trump has boasted about his cognitive abilities. In his last term, he made similar claims, even reciting memorable parts of the test like the now-famous phrase- "Man, Woman, Person, Camera, TV."

What Is the Cognitive Test Trump Took?

The test in question is the Montreal Cognitive Assessment (MoCA), a standardized screening tool developed in 1996 by neurologist Dr. Ziad Nasreddine. It’s widely used to detect mild cognitive impairment and early signs of Alzheimer's disease. Despite its simplicity for cognitively healthy individuals, the test is a powerful tool in neurological diagnostics.

MoCA tests several areas of brain function such as memory, attention, language, visuospatial abilities, and executive functions. It takes about 10 minutes and is commonly utilized by neurologists and primary care physicians to screen for cognitive impairments in persons aged 65 years and older.

President Trump claimed that he got every question correct — and for a cognitively healthy person, that is what is expected. But what is the MoCA, and are its last questions as hard as Trump claims?

1. Visuospatial and Executive Function Tasks

The test starts with a series of drawing exercises that involve:

• Drawing a clock indicating a particular time, e.g., 10 past 11.
• Copying a three-dimensional cube.

These exercises assess spatial knowledge, attention, and planning abilities — tasks that can decline with age or neurological deterioration.

2. Identification and Naming

These are illustrated animals — often a lion, camel, and rhinoceros — and participants are requested to identify them. This task appears straightforward but can be sensitive to problems with recall of language or semantic memory.

3. Delayed Recall and Memory

One of the more difficult sections of the test is when subjects are required to recall a series of five unrelated words. Later in the test, they are required to recall these same words without cues. This delayed recall section often uncovers early memory lapses.

4. Attention and Language Repetition

In the following section, items involve the repetition of strings of numbers forward and backward and simple subtraction items (e.g., subtract 7 from 100 consecutively). This assesses working memory and attention.

5. Verbal Fluency and Abstraction

Here, the subjects are required to say as many words as possible beginning with the letter "F" within 60 seconds. Subsequently, they have to describe similarities of two things — for example, how a train and a bicycle are similar (both are means of transport).

6. Orientation

The last section of the test tests an individual's sense of time and place — requesting that the subject give the present date, day of the week, month, year, and place.

How Difficult Is It, Really?

When asked about the difficulty of the test, Trump said, "I'll bet you couldn't even answer the last five questions. They get very hard." While certain sections, such as delayed recall and abstraction, may be challenging for people with early indicators of cognitive impairment, experts explain that the test is not intended to be excessively difficult for non-impaired individuals.

"The MoCA is not a test of intelligence," explains Dr. Sarah Williams, a Johns Hopkins Medicine neurologist. "It's intended to screen for very subtle indicators of cognitive decline. If you are cognitively normal, it will be very easy."

Cognitive Testing and Presidential Transparency

Trump's insistence on taking cognitive testing is less about boasting rights — it is also a sign of larger public anxieties surrounding aging leaders and their cognitive abilities. With both leading presidential candidates now over their late 70s and early 80s, mental sharpness issues have become an overarching theme in American politics.

Trump’s repeated willingness to undergo and publicize the results of cognitive testing could be interpreted as a strategic move to address those concerns head-on. “The American people want a mentally sharp president,” he said. “I think I’ve proven that.”

During a recent visit to tribal communities in Arizona and New Mexico this week, US Health Secretary Robert F Kennedy Jr emphasized the importance of preventing chronic disease among the Native American and Alaska Native population. Is it targeting them? Because behind the scenes, a crucial health initiative that had long served those very communities is being dismantled. This will leave many tribal leaders alarmed and confused.

The initiative in question, Healthy Tribes, was part of the Centers for Disease Control and Prevention (CDC) and allocated $32.5 million annually to support culturally grounded programs focused on chronic disease prevention through traditional foods, medicine, and community engagement. As of early April, the program was also gutted due to workforce reductions at the CDC. Emails to tribal health organizations also confirmed that positions central to administering Healthy Tribes were in fact, being eliminated.

A Silent Rollback That Said A Lot

Kennedy’s public appearances, including a hike with the Navajo Nation president and a visit to a Native health center in Phoenix, made no mention of the program’s fate. He also moderated a panel at the Tribal Self-Governance Conference but avoided public questions. While he has said Native health is a top priority, his silence on the abrupt restructuring of Healthy Tribes has drawn criticism.

Tribal leaders now fear the rollback is part of a broader effort by the Trump administration to dismantle diversity, equity, and inclusion (DEI) initiatives. However, Native leaders have pushed back against being categorized as such, asserting that tribal support is a legal obligation under treaties and federal law—not a diversity measure.

'A Violation of Trust'

The federal government has a trust responsibility to tribal nations, which includes ensuring access to healthcare, education, and public safety. Leaders like W. Ron Allen of the Jamestown S’Klallam Tribe call the recent cuts “a violation of trust.” He said he reminded Kennedy during their private conversation that tribes are already underfunded and rely heavily on supplementary programs like Healthy Tribes.

One of the key concerns is the lack of tribal consultation—a legal requirement for federal actions affecting Native communities. Tribes were not consulted before the layoffs, echoing similar frustrations after mass terminations at the Indian Health Service earlier this year were temporarily rescinded following backlash.

What Is The Ground-Level Reality?

For tribal health facilities, these cuts have an immediate and grave implications.

For instance, in Seattle, Healthy Tribes funded GATHER. This was a program that blended traditional medicine with modern care. Plants from community gardens were also used in this treatment, and traditional healers worked alongside clinical staff. However, now, he communication with the grant administrators has been broken down.

In Los Angeles, Healthy Tribes funds youth-elder mentorship programs among Native and Alaska Native communities. The abrupt staffing changes have left administrators unclear about how or if these initiatives will at all continue.

Native leaders stress that their status is political, not racial, a key legal distinction. “We are not DEI,” said Gila River Indian Community Governor Stephen Roe Lewis, warning new federal officials against viewing tribes through a racial equity lens rather than honoring treaty-based obligations.

For now, tribal communities remain in limbo—concerned that Kennedy’s words on improving Native health aren’t matching federal actions that could ultimately set them back.